(Reuters) – Boehringer Ingelheim will pay $13.5 million to resolve claims by state attorneys general that the pharmaceutical company used deceptive and misleading marketing to promote the use of four of its drugs for unapproved purposes.
The settlement was announced on Wednesday by attorneys general in 50 states to resolve allegations centered on how the drugmaker marketed its prescription drugs Aggrenox, Micardis, Atrovent and Combivent.
